Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis

Author(s): Ammar Al-Chalabi, Vineeta B. Tripathi

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 7 , Issue 1 , 2008

Become EABM
Become Reviewer
Call for Editor


Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of ALS, usually within 3 to 5 years of symptom onset. The lack of effective therapy means that although the incidence is comparable to that of multiple sclerosis, the prevalence is low. The causes of ALS are largely unknown, but the only disease-modifying therapy, riluzole, was designed based on one hypothesis of disease causation, the excitotoxic hypothesis. In this paper we will review current ideas about the causes of ALS and the therapeutic opportunities they suggest.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [11 - 19]
Pages: 9
DOI: 10.2174/187152708783885110

Article Metrics

PDF: 16